SCHEMBL6548765

SCHEMBL6548765

Cc1ccc(S(=O)(=O)c2ccc(F)c3ccccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
COMT P21964 2/20 0.50
ALDH1A1 P00352 3/20 0.49
TSHR P16473 1/20 0.49
GAA P10253 3/20 0.48
GRM5 P41594 2/20 0.45
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTR6 P50406 2/20 0.43
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
KDM4E B2RXH2 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
EGFR P00533 1/20 0.42
SRC P12931 1/20 0.42
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6548757 0.86 ALDH1A1 (0.54) ALDH1A1TSHRGAAHTTHTR6
SCHEMBL14135916 0.83 COMT (0.52) COMTALDH1A1GAAGRM5HTT
SCHEMBL6549076 0.80 TP53 (0.49) ALDH1A1TSHRGAAHTTKDM4E
SCHEMBL3619327 0.76 MCL1 (0.53) ALDH1A1GAAHTTSMN1; SMN2NPSR1
SCHEMBL9587035 0.76 HTR6 (0.70) COMTALDH1A1GAAHTTSMN1; SMN2
SCHEMBL31000980 0.76 GAA (0.68) ALDH1A1GAAHTTSMN1; SMN2HTR6
SCHEMBL11853033 0.76 GAA (0.68) ALDH1A1GAAHTTSMN1; SMN2HTR6
SCHEMBL4573139 0.74 ALDH1A1 (0.53) ALDH1A1TSHRGAAHTTNPSR1
SCHEMBL30999723 0.73 HTR6 (0.62) TSHRGAAHTTHTR6NPSR1
SCHEMBL28550814 0.73 ALDH1A1 (0.51) ALDH1A1TSHRGAAHTTKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478361-A2 ARYLSULFONE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20030220325-A1 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling PHARMACIA & UPJOHN COMPANY 2003-11-27 US disclosed
WO-2003072558-A2 ARYLSULFONE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220325-A1 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling HTR6, TPH1, HTR5A COMT 663/4885ALDH1A1 593/4885TSHR 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.